Edition:
India

Brainstorm Cell Therapeutics Inc (BCLI.OQ)

BCLI.OQ on NASDAQ Stock Exchange Capital Market

3.64USD
23 Aug 2019
Change (% chg)

-- (--)
Prev Close
$3.64
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
20,170
52-wk High
$4.50
52-wk Low
$2.95

Latest Key Developments (Source: Significant Developments)

Brainstorm Cell Therapeutics Posts Q2 Loss Per Share of $0.23
Tuesday, 13 Aug 2019 

Aug 13 (Reuters) - Brainstorm Cell Therapeutics Inc ::BRAINSTORM ANNOUNCES FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2019 AND PROVIDES A CORPORATE UPDATE.Q2 LOSS PER SHARE $0.23.AS OF AUGUST 6, 2019, CASH, CASH EQUIVALENTS, AND SHORT-TERM BANK DEPOSITS WERE $4.5 MILLION..  Full Article

Brainstorm Announces Grant Of An Additional New European Patent For Nurown
Tuesday, 26 Mar 2019 

March 26 (Reuters) - Brainstorm Cell Therapeutics Inc ::BRAINSTORM ANNOUNCES GRANT OF AN ADDITIONAL NEW EUROPEAN PATENT FOR NUROWN®.BRAINSTORM CELL THERAPEUTICS INC - EUROPEAN PATENT OFFICE GRANTED EUROPEAN-WIDE PATENT TITLED 'MESENCHYMAL STEM CELLS FOR TREATMENT OF CNS DISEASES.  Full Article

Brainstorm Cell-Application To Allow Als Patient Access To Nurown Under Hospital Exemption Pathway Was Recently Approved By Israeli Health Ministry
Tuesday, 12 Mar 2019 

March 12 (Reuters) - Brainstorm Cell Therapeutics Inc ::BRAINSTORM CELL-APPLICATION TO ALLOW ALS PATIENT ACCESS TO NUROWN UNDER HOSPITAL EXEMPTION PATHWAY WAS RECENTLY APPROVED BY ISRAELI HEALTH MINISTRY.BRAINSTORM CELL THERAPEUTICS - IN 2017, SUBMITTED APPLICATION IN ISRAEL TO ALLOW ALS PATIENT ACCESS TO NUROWN(REG) UNDER HOSPITAL EXEMPTION PATHWAY.  Full Article

Brainstorm Cell Therapeutics - FDA Accepts Co’s Nurown IND Application
Monday, 17 Dec 2018 

Dec 17 (Reuters) - Brainstorm Cell Therapeutics Inc ::FDA ACCEPTS BRAINSTORM’S NUROWN® IND APPLICATION FOR PROGRESSIVE MULTIPLE SCLEROSIS.BRAINSTORM CELL THERAPEUTICS - THROUGH TRIAL, CO ADVANCING TREATMENT MODALITY INTO CLINICAL-STAGE TESTING FOR PROGRESSIVE MS IN EARLY 2019.  Full Article

Brainstorm Cell Therapeutics - Submits IND for Nurown In Progressive Multiple Sclerosis
Monday, 19 Nov 2018 

Nov 19 (Reuters) - Brainstorm Cell Therapeutics Inc ::BRAINSTORM CELL THERAPEUTICS - SUBMITTED IND APPLICATION WITH FDA TO INITIATE PHASE 2 STUDY OF NUROWN IN PATIENTS WITH PROGRESSIVE MS.  Full Article

Brainstorm Cell Therapeutics reports Q3 results
Monday, 29 Oct 2018 

Oct 29 (Reuters) - Brainstorm Cell Therapeutics Inc ::BRAINSTORM ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER OF 2018 AND PROVIDES A CORPORATE UPDATE.Q3 LOSS PER SHARE $0.15.FOLLOWING SUCCESSFUL FDA PRE-IND MEETING, BRAINSTORM WILL FILE AN IND FOR NUROWN IN A SECOND CLINICAL INDICATION.  Full Article

BrainStorm Cell Therapuetics Reports Q1 Loss Per Share Of $0.12
Monday, 14 May 2018 

May 14 (Reuters) - Brainstorm Cell Therapuetics Inc ::BRAINSTORM ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE AND CLINICAL HIGHLIGHTS.Q1 LOSS PER SHARE $0.12.  Full Article

Brainstorm Cell Received Good Manufacturing Practice Approval From Israel Ministry Of Health
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Brainstorm Cell Therapuetics Inc ::BRAINSTORM CELL THERAPUETICS - RECEIVED GOOD MANUFACTURING PRACTICE APPROVAL FROM ISRAEL MINISTRY OF HEALTH FOR ISRAELI CONTRACT MANUFACTURING FACILITY.BRAINSTORM CELL THERAPUETICS INC - APPROVAL ADVANCES CO'S APPLICATION TO ISRAEL MOH FOR TREATMENT OF ALS PATIENTS IN ISRAEL FOR A FEE.  Full Article

Brainstorm Cell Therapuetics names Eyal Rubin CFO
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Brainstorm Cell Therapuetics Inc :Brainstorm strengthens executive team: appoints Eyal Rubin as chief financial officer.Eyal Rubin joins co from Teva Pharmaceutical Industries Ltd.  Full Article

Brainstorm reports Q3 loss per share of $0.13
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - Brainstorm Cell Therapuetics Inc :Brainstorm announces third quarter 2017 financial results.Q3 loss per share $0.13.  Full Article